AI Article Synopsis
- Lung carcinosarcoma is a rare lung cancer, making large-scale clinical studies challenging, and treatments are often based on limited empirical evidence.
- A case study highlights a 73-year-old woman who experienced postoperative recurrence of this cancer, with genetic testing showing the EGFR exon21 L858R mutation.
- The patient was successfully treated with a combination of erlotinib and ramucirumab, suggesting this combo as a viable option for managing EGFR mutation-positive lung carcinosarcoma.
Article Abstract
Lung carcinosarcoma is acknowledged as a rare form of lung cancer. Due to its rarity, the inability to conduct large-scale clinical trials and interventions is currently carried out based on empirical evidence. In this study, we report the case of a 73-year-old female patient diagnosed with postoperative recurrence of lung carcinosarcoma. The resected tumor was diagnosed as lung carcinosarcoma, and genetic testing revealed the presence of the epidermal growth factor receptor (EGFR) exon21 L858R. Approximately 2 years postoperatively, the tumor recurred and the patient was treated with erlotinib plus ramucirumab, which were effective in controlling metastatic disease. Erlotinib plus ramucirumab is therefore a treatment option for EGFR mutation-positive lung carcinosarcoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693942 | PMC |
| http://dx.doi.org/10.1111/1759-7714.15134 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!